A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)
Latest Information Update: 26 Feb 2025
At a glance
- Drugs OATD-01 (Primary)
- Indications Pulmonary sarcoidosis
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms KITE
- Sponsors Molecure
Most Recent Events
- 11 Sep 2024 Study design were presented at the 34th Annual Congress of the European Respiratory Society.
- 10 Jul 2024 Planned End Date changed from 1 Mar 2026 to 1 Dec 2025.
- 10 Jul 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Nov 2025.